Clinical Trial Update: An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating APX001 for candidemia in non-neutropenic patients has completed and results have been posted, detailing efficacy and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia

Drugs mentioned

• APX001 (fosmanogepix)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Candidemia | Phase 2 | Status: COMPLETED | Results posted: 2021-08-05